ClearPoint Neuro (CLPT) AI Stock Analysis

• Market Cap: $331.99M
• Dividend Yield: N/A
• Average Volume (3M): 894.99K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.67
• Revenue Growth: 12.83%
• EPS Growth: -19.53%
• Country: US
• Employees: 115
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.26
• Shares Outstanding: 29,748,308
• 10 Day Avg. Volume: 1,159,456
• 30 Day Avg. Volume: 894,994
• PEG Ratio: -0.53
• Price to Book (P/B): 13.82
• Price to Sales (P/S): 10.48
• P/FCF Ratio: -15.84
• Enterprise Value/Market Cap: 1.04
• Enterprise Value/Revenue: 9.31
• Enterprise Value/Gross Profit: 15.17
• Enterprise Value/Ebitda: -14.25
• 1Y Price Target: $24.00
• Price Target Upside: -12.15% Downside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): -0.8
• Revenue Forecast (FY): $55.50M

• Rating: 47 Neutral
• Price Target: $11.00 ▼(-59.74% Downside)
• Action: Reiterated Date: 03/17/26
• Date: Action: Reiterated 03/17/26

The score is held down primarily by weak financial quality (large losses, heavier leverage, and increased cash burn) and bearish technical trend signals. Partially offsetting these are a more positive earnings-call setup with strong 2026 revenue guidance and sustained ~61% gross margins, while valuation remains challenged due to negative earnings and no dividend support.

Positive Factors

Consistent multi-year revenue growth

Eleven straight years of top-line growth and recent 17.8% YoY revenue expansion indicate durable commercial traction. A growing installed base and rising procedure volumes support recurring disposable and service revenue, improving predictability of cash inflows over the medium term.

Sustained high gross margins (~61%)

A ~61% gross margin provides structural profitability leverage: it cushions R&D and SG&A investments, supports reinvestment for commercialization, and means incremental procedure growth can translate to outsized gross-profit gains versus revenue, aiding long-term margin sustainability.

Broad partner ecosystem and clinical pipeline

A diversified set of biopharma partners and 25+ trials create multiple, staggered potential commercial and regulatory catalysts. This ecosystem reduces single-customer concentration, expands addressable procedure volume, and gives durable optionality if individual programs face delays.

Negative Factors

Heavy and worsening cash burn

Large negative operating and free cash flows materially raise near-term funding needs and dilute financial flexibility. Persistent cash burn increases reliance on financing, heightens dilution risk, and constrains the company's ability to self-fund commercial scale-up and capital projects over the next 2–6 months.

Sharp increase in debt and leverage

A material rise in debt tightens covenant and liquidity headroom and raises fixed interest costs. Higher leverage reduces strategic flexibility, increases financing cost sensitivity, and amplifies pressure to generate positive operating cash flow to service debt rather than fund growth initiatives.

Regulatory uncertainty and partner-timeline exposure

Revenue upside is linked to external clinical and regulatory outcomes; recent stricter FDA positioning removed some near-term commercial prospects. Dependence on partner trial progress and approvals means revenue timing and scale remain uncertain, limiting reliable short-to-medium term visibility.

ClearPoint Neuro Business Overview & Revenue Model

Company Description

ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. The company develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under direct, and intra-procedural magnetic resonance imaging (MRI) guidance. It offers ClearPoint system for the insertion of deep brain stimulation electrodes and biopsy needles, and the infusion of pharmaceuticals and laser catheters into the brain; and ClearPoint Neuro Navigation System, an MRI suite. It has license and collaboration agreements with Boston Scientific Corporation, The Johns Hopkins University, Clinical Laserthermia Systems Americas Inc, Koninklijke Philips N.V., Blackrock Neurotech, and University of California and San Francisco. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.

How the Company Makes Money

ClearPoint Neuro primarily generates revenue by selling and supporting its neurosurgical navigation platform and the consumables used with it. Key revenue streams typically include: (1) capital equipment sales (and/or placements) of the ClearPoint system to hospitals and clinical centers; (2) recurring revenue from single-use disposables and procedure-related components consumed each time a ClearPoint-guided case is performed (a utilization-driven stream that can scale with procedure volume at installed sites); and (3) service, support, and other related revenue tied to maintaining and supporting installed systems. The company’s earnings potential is influenced by the size of its installed base, procedure adoption/volume at customer sites (which drives disposable pull-through), and collaborations with biopharma/clinical partners developing therapies that require precise intracranial delivery using MRI-guided navigation. Specific partnership terms, pricing, and the relative contribution of each stream are null.

ClearPoint Neuro Financial Statement Overview

Summary

Strong multi-year revenue growth and solid gross profit, but fundamentals are constrained by deep ongoing net losses, sharply higher leverage in 2025 (debt jumped to $58.2M), and significantly worsening cash burn (2025 operating cash flow -$23.9M; FCF -$24.4M).

Income Statement

Revenue has grown consistently from $12.8M (2020) to $37.0M (2025), with growth still positive in 2025 (+7.7%) after a strong 2024 (+31.0%). Gross profit remains solid (about $22.7M on $37.0M revenue in 2025), but the company is still deeply unprofitable: net income was -$25.5M in 2025, and operating losses have not shown sustained improvement versus prior years. Overall, the top-line trajectory is a clear positive, but persistent large losses keep the score low.

Balance Sheet

Balance sheet risk increased sharply in 2025 as total debt jumped to $58.2M from $3.6M in 2024, while equity is $28.0M. This meaningfully raises leverage and reduces financial flexibility versus the prior year, even though total assets also rose to $97.7M. Equity remains positive, but ongoing losses and the step-up in debt are key weaknesses.

Cash Flow

Cash burn remains heavy and worsened in 2025: operating cash flow was -$23.9M and free cash flow was -$24.4M, compared with -$9.0M and -$9.2M in 2024. While free cash flow growth appears positive in 2025 (reflecting year-to-year volatility), the absolute level of negative cash flow is large and implies continued funding needs. This weak cash profile is a major constraint.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	36.97M	31.39M	23.95M	20.55M	16.30M
Gross Profit	22.69M	19.12M	13.61M	13.53M	11.12M
EBITDA	-24.16M	-17.84M	-20.99M	-15.58M	-12.74M
Net Income	-25.54M	-18.91M	-22.09M	-16.43M	-14.41M
Balance Sheet
Total Assets	97.75M	39.19M	42.66M	55.49M	65.58M
Cash, Cash Equivalents and Short-Term Investments	45.92M	20.10M	23.14M	37.49M	54.11M
Total Debt	58.23M	3.57M	13.94M	11.99M	12.28M
Total Liabilities	69.73M	13.80M	21.49M	18.60M	16.79M
Stockholders Equity	28.02M	25.39M	21.17M	36.89M	48.79M
Cash Flow
Free Cash Flow	-24.45M	-9.22M	-14.44M	-16.42M	-12.87M
Operating Cash Flow	-23.93M	-8.95M	-13.72M	-16.17M	-12.70M
Investing Cash Flow	615.00K	-275.00K	8.95M	-10.74M	-168.00K
Financing Cash Flow	50.18M	6.19M	296.00K	409.00K	46.88M

ClearPoint Neuro Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 27.32
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CLPT, the sentiment is Negative. The current price of 27.32 is above the 20-day moving average (MA) of 12.00, above the 50-day MA of 13.27, and above the 200-day MA of 14.36, indicating a bearish trend. The MACD of -0.72 indicates Negative momentum. The RSI at 44.17 is Neutral, neither overbought nor oversold. The STOCH value of 72.12 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CLPT.

ClearPoint Neuro Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BVS	65 Neutral	$747.56M	21.81	4.97%	―	1.58%	―
SIBN	56 Neutral	$567.08M	-45.38	-12.91%	―	23.27%	43.90%
AVNS	54 Neutral	$632.91M	35.21	-8.56%	―	2.70%	-3090.51%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
OFIX	50 Neutral	$482.94M	-6.56	-20.38%	―	4.31%	3.26%
CLPT	47 Neutral	$331.99M	―	-122.17%	―	12.83%	-19.53%

ClearPoint Neuro Corporate Events

ClearPoint Neuro Reports Record 2025 Results, Expands Growth Outlook

ClearPoint Neuro, Inc., based in Solana Beach, Calif., is a global medical device and therapy-enabling company focused on precise navigation for the brain and spine. Its portfolio spans biologics and drug delivery tools, neurosurgery navigation and therapy products, capital equipment and software, and, following its IRRAS Holdings acquisition, neurocritical care solutions, while it targets pre-commercial and future commercial cell and gene therapy delivery with support for more than 60 biopharma partners and over 25 global clinical trials.

ClearPoint Neuro reported record 2025 results on March 17, 2026, with full-year revenue rising 18% to $37.0 million, marking its eleventh straight year of growth, and fourth-quarter revenue up 34% to $10.4 million, while gross margins held at 61–62%. The November 2025 acquisition of IRRAS Holdings expanded the business into neurocritical care, contributed IRRAflow revenue, and was backed by an additional $20 million financing access and a year-end cash balance of $45.9 million, supporting the company’s “Fast. Forward.” growth strategy in a $1 billion market and positioning it for further double-digit expansion and a projected 2026 revenue range of $52–56 million.

The most recent analyst rating on (CLPT) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on ClearPoint Neuro stock, see the CLPT Stock Forecast page.

ClearPoint Neuro Restructures IRRAS Subsidiary Under Debt Agreement

On December 29, 2025, ClearPoint Neuro entered into a consent agreement with CALW SA LLC and TPC Investments III LP, an affiliate of Oberland Capital Management, related to an existing Note Purchase Agreement originally executed in May 2025 and amended in November 2025. Under the consent, ClearPoint Neuro agreed to complete by January 15, 2026 an internal reorganization of its Swedish subsidiary IRRAS AB, including transferring all equity interests in IRRAS USA, Inc. from IRRAS AB to ClearPoint or its direct U.S. subsidiary in exchange for a subordinated intercompany note, and to take additional steps so that IRRAS AB qualifies as an “Immaterial Foreign Subsidiary” under the Note Purchase Agreement. The consent preserves the material economic terms of the company’s financing arrangements while restructuring ownership of the IRRAS assets, which may streamline the company’s capital structure and compliance with its debt covenants following the IRRAS acquisition.

The most recent analyst rating on (CLPT) stock is a Hold with a $14.50 price target. To see the full list of analyst forecasts on ClearPoint Neuro stock, see the CLPT Stock Forecast page.